Want to see ZVRA full AI Analyst Report?
ZVRA Stock Chart & Stats
$9.52
-$2.99(-23.92%)
At close: 4:00 PM EDT
$9.52
-$2.99(-23.92%)
Day’s Range― - ―
52-Week Range$7.16 - $15.04
Previous CloseN/A
Volume6.94M
Average Volume (3M)1.53M
Market Cap
$663.91M
Enterprise Value$659.49
Total Cash (Recent Filing)$221.57M
Total Debt (Recent Filing)$1.50M
Price to Earnings (P/E)11.8
Beta1.05
Next Earnings
Nov 11, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.96
Shares Outstanding59,383,780
10 Day Avg. Volume1,514,717
30 Day Avg. Volume1,529,144
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.20
Price to Sales (P/S)4.65
P/FCF Ratio-203.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$25.25Price Target Upside165.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.11
Revenue Forecast (FY)$152.22M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetElimination of debt materially reduces financial risk and interest burden, improving flexibility to fund commercialization, R&D, or M&A without reliance on external financing. A de-levered capital structure supports durable operational resilience across 2–6 months and beyond.
Positive Free Cash Flow GenerationConsistent positive FCF indicates reported earnings largely convert to cash, enabling reinvestment, non-dilutive capital returns (or strategic buys) and reduced refinancing risk. While prior years were inconsistent, current cash conversion supports durable funding of commercialization and trials.
Commercial Traction And Guideline Inclusion For MIPLYFFAGuideline inclusion and an extensive clinical dataset create a structural advantage for physician adoption and payer acceptance in a narrow orphan market. This supports sustainable market share, durable revenue streams and improves reimbursement prospects over multiple years.
Bears Say
Headline Profitability Driven By One-time GainReliance on a large non-recurring gain to produce headline profits masks underlying operating profitability. If one-time proceeds are exhausted, reported earnings could revert, pressuring margins and cash flow consistency and complicating medium-term planning for investors and lenders.
Historic Operating And Earnings VolatilityLarge swings between loss-making years and outsized profitability reduce predictability of future cash flows and returns. Such volatility complicates resource allocation, raises execution risk for commercialization investment, and increases sensitivity to single-period events.
Slow Event Accrual In Pivotal DiSCOVER TrialEvent-driven delays in a Phase III pivotal study extend regulatory timelines and the time to potential approval or label expansion. Prolonged accrual risks higher trial costs, delayed value realization from the asset, and greater dependence on commercial portfolio performance in the interim.
Zevra Therapeutics News
ZVRA FAQ
What was Zevra Therapeutics, Inc.’s price range in the past 12 months?
Zevra Therapeutics, Inc. lowest stock price was $7.16 and its highest was $15.04 in the past 12 months.
What is Zevra Therapeutics, Inc.’s market cap?
Zevra Therapeutics, Inc.’s market cap is $663.91M.
When is Zevra Therapeutics, Inc.’s upcoming earnings report date?
Zevra Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.
How were Zevra Therapeutics, Inc.’s earnings last quarter?
Zevra Therapeutics, Inc. released its earnings results on Aug 05, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03.
Is Zevra Therapeutics, Inc. overvalued?
According to Wall Street analysts Zevra Therapeutics, Inc.’s price is currently Undervalued.
Does Zevra Therapeutics, Inc. pay dividends?
Zevra Therapeutics, Inc. does not currently pay dividends.
What is Zevra Therapeutics, Inc.’s EPS estimate?
Zevra Therapeutics, Inc.’s EPS estimate is 0.16.
How many shares outstanding does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc. has 59,383,780 shares outstanding.
What happened to Zevra Therapeutics, Inc.’s price movement after its last earnings report?
Zevra Therapeutics, Inc. reported an EPS of $0.14 in its last earnings report, beating expectations of $0.11. Following the earnings report the stock price went up 12.821%.
Which hedge fund is a major shareholder of Zevra Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ZVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zevra Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.25 (165.23% Upside)
$25.25 (165.23% Upside)
Blogger Sentiment
Bullish
ZVRA Sentiment 91%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 113.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $138.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
18.12%
Trailing 12-Months
Company Description
Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
ZVRA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong progress on multiple fronts: very robust revenue growth (+78% YoY), positive reported net income driven by a strategic asset sale, a clean balance sheet with no debt and meaningful commercial validation for MIPLYFFA (170 enrollments, guideline inclusion, broad clinical dataset). At the same time, management flagged a number of operational and execution items to monitor — elevated operating expenses, a sizeable tax provision, reliance on a one-time sale for headline profitability, variability in EAP and international orders, modest quarter-over-quarter prescription momentum (9 new enrollment forms in Q1), and slow event accrual in the Celiprolol trial. Overall, the positives around commercial traction, cash position and strategic portfolio actions outweigh the transitory and execution-related headwinds, but the underlying operating performance and trial timelines warrant continued attention.View all ZVRA earnings summariesZVRA Stock 12 Month Forecast
Average Price Target
$25.25
▲(165.23% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Prothena
―
Ocugen
―
Corvus Pharmaceuticals
―
Solid Biosciences
―
Ownership Overview
1.48% Insiders
13.25% Mutual Funds
22.38% Other Institutional Investors
47.61% Public Companies and Individual Investors